- Home
- PCRX vs RXST Comparison
PCRX vs RXST Comparison
Compare PCRX & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- RXST
- Stock Information
- Founded
- PCRX 2006
- RXST 1997
- Country
- PCRX United States
- RXST United States
- Employees
- PCRX N/A
- RXST N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PCRX Health Care
- RXST Health Care
- Exchange
- PCRX Nasdaq
- RXST Nasdaq
- Market Cap
- PCRX 1.1B
- RXST 1.0B
- IPO Year
- PCRX 2011
- RXST 2021
- Fundamental
- Price
- PCRX $24.65
- RXST $14.43
- Analyst Decision
- PCRX Buy
- RXST Buy
- Analyst Count
- PCRX 9
- RXST 10
- Target Price
- PCRX $30.11
- RXST $38.50
- AVG Volume (30 Days)
- PCRX 1.2M
- RXST 1.2M
- Earning Date
- PCRX 05-06-2025
- RXST 05-07-2025
- Dividend Yield
- PCRX N/A
- RXST N/A
- EPS Growth
- PCRX N/A
- RXST N/A
- EPS
- PCRX N/A
- RXST N/A
- Revenue
- PCRX $700,966,000.00
- RXST $139,927,000.00
- Revenue This Year
- PCRX $9.48
- RXST $24.34
- Revenue Next Year
- PCRX $11.31
- RXST $21.83
- P/E Ratio
- PCRX N/A
- RXST N/A
- Revenue Growth
- PCRX 3.85
- RXST 57.09
- 52 Week Low
- PCRX $11.16
- RXST $13.50
- 52 Week High
- PCRX $31.67
- RXST $66.54
- Technical
- Relative Strength Index (RSI)
- PCRX 51.22
- RXST 25.56
- Support Level
- PCRX $24.10
- RXST $13.79
- Resistance Level
- PCRX $25.35
- RXST $14.93
- Average True Range (ATR)
- PCRX 1.49
- RXST 1.34
- MACD
- PCRX 0.01
- RXST -0.29
- Stochastic Oscillator
- PCRX 48.89
- RXST 9.78
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.